PERSON
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
Sentynl Therapeutics Receives FDA Approval for ZYCUBO, First US Treatment for Rare Menkes Disease
Sentynl Therapeutics; ZYCUBO; FDA approval; Menkes disease; copper histidinate; Zydus Lifesciences
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Pfizer; Obesity Drugs; Metsera; Phase III Trials; Albert Bourla; JPM26; Patent Cliff
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos
FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]
FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02
FDA Announces Flexible Manufacturing Approach for Cell and Gene Therapies on January 11, 2026
FDA; cell and gene therapies; CGT; manufacturing flexibility; CMC requirements; Marty Makary
Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia
Eisai; Nuvation Bio; taletrectinib; ROS1+ NSCLC; licensing agreement; lung cancer
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin; MIRACLE trial; Annamycin; WP1066; AML; clinical trials; 2026 milestones
Dr Melanie Ivarsson Appointed CEO of Health Data Research Service
Dr Melanie Ivarsson; Health Data Research Service; HDRS; CEO appointment; UK health data; medical research
BioXcel Therapeutics Expands Leadership Team with Mark Pavao as Acting Chief Commercial Officer
BioXcel Therapeutics; Mark Pavao; IGALMI; Chief Commercial Officer; sNDA; at-home treatment